Goodwin, White & Case Build BridgeBio's $949M SPAC Deal
By Jade Martinez-Pogue · February 28, 2025, 12:27 PM EST
Clinical-stage biopharmaceutical company BridgeBio Oncology Therapeutics, advised by Goodwin Procter LLP, on Friday announced plans to go public via a merger with special purpose acquisition company Helix Acquisition Corp. II, advised...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login